BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38460672)

  • 1. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
    Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
    Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
    Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
    Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
    Ruiz-Cordero R; Rao P; Li L; Qi Y; Atherton D; Peng B; Singh RR; Kim TB; Kawakami F; Routbort MJ; Alouch N; Chow CB; Tang X; Lu W; Brimo F; Matin SF; Wood CG; Tannir NM; Wistuba II; Chen K; Wang J; Medeiros LJ; Karam JA; Tamboli P; Sircar K
    Mod Pathol; 2019 Nov; 32(11):1698-1707. PubMed ID: 31231128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities.
    Hes O; Trpkov K
    Mod Pathol; 2022 Sep; 35(9):1140-1150. PubMed ID: 35273336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
    Tan MH; Wong CF; Tan HL; Yang XJ; Ditlev J; Matsuda D; Khoo SK; Sugimura J; Fujioka T; Furge KA; Kort E; Giraud S; Ferlicot S; Vielh P; Amsellem-Ouazana D; Debré B; Flam T; Thiounn N; Zerbib M; Benoît G; Droupy S; Molinié V; Vieillefond A; Tan PH; Richard S; Teh BT
    BMC Cancer; 2010 May; 10():196. PubMed ID: 20462447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
    Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
    Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
    Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
    Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
    Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
    Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.
    An J; Park CK; Kim M; Joo JW; Cho NH
    Virchows Arch; 2021 Mar; 478(3):459-470. PubMed ID: 32816058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
    Foix MP; Dunatov A; Martinek P; Mundó EC; Suster S; Sperga M; Lopez JI; Ulamec M; Bulimbasic S; Montiel DP; Alaghehbandan R; Peckova K; Pivovarcikova K; Ondrej D; Rotterova P; Skenderi F; Prochazkova K; Dusek M; Hora M; Michal M; Hes O
    Virchows Arch; 2016 Dec; 469(6):669-678. PubMed ID: 27631338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
    Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
    Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathological features of low-grade oncocytic renal tumor (CD117-negative, cytokeratin 7-positive): report of seven cases].
    Xie B; Cheng LC; Yin GL; Liu BA; Hu ZL; Tong K
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):719-725. PubMed ID: 35922161
    [No Abstract]   [Full Text] [Related]  

  • 14. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
    Mansoor M; Siadat F; Trpkov K
    Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomorphology, immunoprofile, and management of renal oncocytic neoplasms.
    Zhu B; Rohan SM; Lin X
    Cancer Cytopathol; 2020 Dec; 128(12):962-970. PubMed ID: 32697415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
    Lüders C; Kristiansen G
    Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists.
    Williamson SR; Gadde R; Trpkov K; Hirsch MS; Srigley JR; Reuter VE; Cheng L; Kunju LP; Barod R; Rogers CG; Delahunt B; Hes O; Eble JN; Zhou M; McKenney JK; Martignoni G; Fleming S; Grignon DJ; Moch H; Gupta NS
    Hum Pathol; 2017 May; 63():149-156. PubMed ID: 28315424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
    Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
    Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.